HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Salvos, Retorts In P&G Board Vote Campaign Continue To Finish Line

This article was originally published in The Pink Sheet

Executive Summary

Firm's tactics against activist investor Nelson Peltz' bid for a board seat include the unusual step of featuring board member Meg Whitman in an investor briefing. Peltz aired TV ads in explaining his bid P&G's hometown, Cincinnati, before it asked him to pull the ads, claiming they were misleading.

You may also be interested in...



Investor Critical Of P&G Management Before Election To Board Follows CEO Out The Door

In tones completely opposite from when Nelson Peltz sought a board seat in 2017, P&G CEO David Taylor and Peltz congratulated each other in P&G’s announcement.

As P&G Board Vote Looms, Activist Investor Peltz Gains Endorsements

As Procter & Gamble prepares for a shareholder vote that could shake up its board and its strategies, proxy advisor Glass, Lewis & Co. recommends shareholders vote in favor of electing Trian Fund Management CEO Nelson Peltz, who's pressing the firm for dramatic operational changes.

Legacy Consumer Health Firms Invest To Compete In Start-Ups' Realm: E-Commerce

J&J, Colgate, P&G and Church & Dwight look to e-commerce to regain market share from smaller, nimble consumer health brands and digital-based retail start-ups, executives say at Barclays Global Consumer Staples conference.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel